ライフサイエンスコーパス: XDR-TB

1 Mortality was higher among XDR-TB cases than among MDR-TB cases (PR, 1.82; 95% CI,

2 exogenous reinfection as a cause of MDR and XDR TB in these settings has not been determined.

3 e [ST] 34 and ST 60, associated with MDR and XDR TB, respectively) were responsible for 85% of reinfe

4 ant mechanism for the development of MDR and XDR TB.

5 needed to reduce the transmission of MDR and XDR TB.

6 MDR and XDR-TB isolates were significantly more likely to belong

7 e to first- and second-line drugs in MDR and XDR-TB.

8 ion, transmission, and evolution of MDR- and XDR-TB in Belarus and will enable improved diagnostics,

9 enetic composition and evolution of MDR- and XDR-TB in the region, we sequenced and analyzed the geno

10 atives for molecular diagnostics of MDR- and XDR-TB.

11 provides ideal conditions for an MDR-TB and XDR-TB epidemic of unparalleled magnitude.

12 easures necessary for controlling MDR-TB and XDR-TB in this context.

13 sful response to the emergence of MDR-TB and XDR-TB will necessitate increased resources for and coll

14 tremely drug resistant organisms (MDR-TB and XDR-TB).

15 vely drug-resistant tuberculosis (MDR-TB and XDR-TB, respectively) has intensified the critical publi

16 Compared with MDR-TB cases, XDR-TB cases were more likely to have disseminated TB di

17 associated with resistance to drugs defining XDR TB.

18 Our approach could enable testing for XDR-TB in point-of-care settings, potentially identifyin

19 quencing and dating analysis to determine if XDR-TB had emerged recently or had ancient antecedents.

20 We collected M/XDR TB isolates from regions of high TB burden in India,

21 assessment of PZA molecular diagnostics in M/XDR TB cases.

22 -/extensively drug-resistant tuberculosis (M/XDR TB), but large studies of mutations as markers of re

23 specificities of mutations associated with M/XDR TB to inform the development of rapid diagnostic met

24 d M. tuberculosis resistance mutations and M/XDR-TB treatment outcomes, limiting our current ability

25 al M. tuberculosis isolates from a diverse M/XDR-TB patient population at three high-burden clinical

26 duration of anti-TB therapy, treatment of M/XDR-TB is very expensive and often associated with adver

27 sistant and extensively drug-resistant TB (M/XDR-TB).

28 vely drug-resistant tuberculosis (XDR-TB) (M/XDR-TB).

29 Some patients with M/XDR-TB may have to be treated with currently available a

30 tment for TB, especially for patients with M/XDR-TB, would be highly desired.

31 eve cure for the majority of patients with M/XDR-TB.

32 al importance in predicting whether the MDR-/XDR-TB epidemic will be sustained across the human popul

33 A total of 83 cases of XDR-TB were reported in the United States from 1993 to 2

34 Control of XDR-TB will require additional interventions, the impact

35 rapid, automated assay for the detection of XDR-TB plus resistance to the drug isoniazid (INH) for p

36 It is unclear whether the emergence of XDR-TB in KwaZulu-Natal was due to recent inadequacies i

37 he aminoglycoside kanamycin is a hallmark of XDR-TB.

38 Estimated incidence of XDR-TB hospitalizations was 7.2 per 100,000 health care

39 The number of XDR-TB cases declined from 18 (0.07% of 25 107 TB cases)

40 identified 23 patients who developed MDR or XDR TB after being treated for less resistant TB between

41 lture-positive TB who later developed MDR or XDR TB in Tugela Ferry, KwaZulu-Natal, South Africa duri

42 ely to be hospitalized with either MDR-TB or XDR-TB than were non-health care workers.

43 than non-health care workers with MDR-TB or XDR-TB were women (78% vs. 47%; P < 0.001), and health c

44 one, expanded culture and DST did not reduce XDR-TB incidence, but they enhanced the impact of transm

45 s in six genes predicted clinically relevant XDR-TB phenotypes with 90 to 98% sensitivity and almost

46 Twenty-six XDR-TB cases (35%) died during treatment, of whom 21 (81

47 Sixteen isolates from six suspected XDR-TB cases were sequenced; five cases were analyzed in

48 (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains have further worsened the TB pandemic.

49 (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains.

50 12 was found to be active against the tested XDR-TB strains and orally active in the serum inhibition

51 e times within each cluster, indicating that XDR TB is currently not widely transmitted.

52 luding the timing of acquisitions leading to XDR-TB in the LAM4 spoligotype, and to calculate the num

53 tibiotics are used as a last resort to treat XDR-TB.

54 y drug-resistant Mycobacterium tuberculosis (XDR-TB) encountered at a London teaching hospital betwee

55 and extensively drug-resistant tuberculosis (XDR-TB) (M/XDR-TB).

56 in extensively drug-resistant tuberculosis (XDR-TB) and HIV co-infected patients in South Africa.

57 of extensively drug-resistant tuberculosis (XDR-TB) has raised global public health concern, given t

58 to extensively drug-resistant tuberculosis (XDR-TB).

59 Although the number of US XDR-TB cases has declined since 1993, coinciding with im

60 olution of resistance within patients, while XDR-TB was acquired through both routes.

61 9 y (34.6, 35.2) assuming only patients with XDR TB received bedaquiline.

62 ld-type and mutant sequences associated with XDR-TB directly from sputum.